World Health Organization Pharmaceutical Import Profile — Pakistan (DGFT 2022–2026)

Name: World Health Organization Pharmaceutical Import Records from India — 4 Products, $4.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

World Health Organization — Pharmaceutical Importer Profile (2026) | 4 Products, $4.4M Trade | TransData Nexus

World Health Organization

Pharmaceutical Importer · Pakistan · Medical Devices & Diagnostics Focus · $4.4M Total Trade · DGFT Verified

World Health Organization is a pharmaceutical importer based in Pakistan with a total trade value of $4.4M across 4 products in 2 therapeutic categories. Based on 200 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. World Health Organization sources from 46 verified Indian suppliers, with Sandoz Private Limited accounting for 16.4% of imports.

World Health Organization — Import Portfolio & Supplier Network

World Health Organization import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to World Health Organization?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sandoz Private Limited	$1.9M	98	16.4%
Medopharm	$1.8M	65	15.3%
Arkray Healthcare Private Limited

What Formulations Does World Health Organization Import?

Formulation	Value	Ships
Diagnostics kits (laboratory reagents	$520.9K	26
Material no. - 44032565 mb adult 360kitint (mfg licence no.: kd-390)	$372.0K	10
Metformin tablets BP 500MG	$350.0K	7
Diphtheria antitoxin IP 10000iu/10ML	$335.5K	17
Material no. - 44032565 mb adult	$327.0K	8
Material no 44103144 mb adult 360kitv1 int mfg licence no kd	$250.0K	5
Harmless medicines zinc oxide ointment 10%, 100g (zinc oxide ointment 10%)	$245.2K	5
Amlodipine besylate tablets USP 5MG 10000 x 100 x 10 -	$184.6K	5
Amlodipine besylate tablets USP 5MG	$161.5K	5
(other medicaments-erythropoietin) erythropoietin injection-repoitin 4000	$132.6K	3
Acetyl salicylic acid 75MG tablets	$132.5K	6
Material no. - 44032565 mb adult 360kit int (mfg licence no.: kd-390	$126.4K	4
Diphtheria antitoxin, 10,000 i.u, lyophilised/liquid, 10 ML	$121.9K	3
Thromboflux 1.5 m.i.u. (lyophilized)	$117.2K	5
Amphonex 50MG (lyop) liposomal	$100.0K	2

World Health Organization imports 462 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Kit	Medical Devices & Diagnostics	$2.6M	107	0.6%	12
2	Diagnostic	Medical Devices & Diagnostics	$691.4K	42	3.8%	4
3	Reagent	Medical Devices & Diagnostics	$691.4K	42	5.3%	3
4	Antitoxin	Other	$450.0K	9	3.4%	5

World Health Organization imports 4 pharmaceutical products across 2 categories into Pakistan totaling $4.4M.

World Health Organization — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

The World Health Organization (WHO) is a specialized agency of the United Nations responsible for international public health. In Pakistan, the WHO operates as a governmental procurement entity, focusing on the acquisition of pharmaceutical products to support public health initiatives. Unlike commercial entities, the WHO's role is not to distribute or retail pharmaceuticals but to procure and supply essential medicines and medical supplies to the Pakistani government and affiliated health organizations. This procurement is integral to Pakistan's healthcare system, ensuring the availability of necessary medical products for public health programs.

2Distribution Network

The WHO's distribution network in Pakistan is extensive, encompassing multiple warehouses strategically located across the country to facilitate efficient storage and distribution of medical supplies. These facilities are equipped with advanced logistics capabilities, including temperature-controlled storage for sensitive pharmaceuticals, to maintain product integrity. The WHO's geographic coverage spans urban and rural areas, ensuring equitable access to medical supplies nationwide. Additionally, the organization coordinates with international suppliers and partners to source and deliver medical products, leveraging global logistics networks to meet Pakistan's healthcare needs.

3Industry Role

Within Pakistan's pharmaceutical supply chain, the WHO functions primarily as a governmental procurement agency. It is not a wholesaler, distributor, or retailer but plays a pivotal role in sourcing and supplying essential medicines and medical supplies to the government and public health institutions. This role is crucial for the implementation of national health programs and the provision of medical care to the population. By procuring pharmaceuticals, the WHO ensures that the government has access to necessary medical products, thereby supporting the overall healthcare infrastructure.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — World Health Organization

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

The WHO's sourcing strategy exhibits a high degree of concentration, with a total import value of $4.4 million USD from India across 200 shipments, encompassing four products in two therapeutic categories. This focused procurement approach suggests a strategic choice to streamline supply chains and maintain consistency in product quality. The top five products imported—Kit, Diagnostic, Reagent, and Antitoxin—account for 100% of the WHO's pharmaceutical imports from India, indicating a specialized and targeted sourcing strategy. This concentration may enhance operational efficiency but also poses risks related to supply chain disruptions.

2Supply Chain Resilience

The WHO's supply chain resilience is closely tied to its sourcing concentration. With a portfolio concentrated entirely on four products from a limited number of suppliers, the organization may face challenges in mitigating supply chain disruptions. The reliance on a select group of suppliers necessitates robust contingency planning and the development of alternative sourcing strategies to ensure continuity of supply. Additionally, the WHO's dependence on Indian suppliers for these critical products underscores the importance of maintaining strong relationships and ensuring compliance with international quality standards to mitigate potential risks.

Importing Pharmaceuticals into Pakistan — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Pakistan

1Regulatory Authority & Framework

In Pakistan, the Drug Regulatory Authority of Pakistan (DRAP) is the primary regulatory body overseeing the pharmaceutical sector. Established under the DRAP Act of 2012, DRAP is responsible for ensuring the quality, safety, and efficacy of therapeutic goods, including pharmaceuticals and medical devices. The regulatory framework governing pharmaceutical imports is primarily based on the Drugs Act of 1976, which outlines the procedures for the import, export, and distribution of drugs. Additionally, the Therapeutic Goods (Import and Export) Rules, 2026, provide detailed guidelines on the import and export procedures for therapeutic goods, including the requirements for obtaining necessary licenses and approvals from DRAP. (dra.gov.pk)

2Import Licensing & GMP

Importers of pharmaceutical products into Pakistan must obtain a Drug Import License (D.I.L.) from DRAP. The application process involves submitting the required documentation through DRAP's online portal, with a typical processing timeline of five days. For the import of finished drugs for commercial purposes, an Import Clearance Certificate is also required, which can be obtained by submitting an application with the necessary documents. Regarding Good Manufacturing Practice (GMP) certification, DRAP recognizes certifications from various international bodies, including the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certifications from recognized authorities to comply with DRAP's standards. (dra.gov.pk)

World Health Organization — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

The WHO's product category focus on medical devices and diagnostics, comprising 89.8% of its imports, reflects a strategic emphasis on essential diagnostic tools and medical equipment critical for public health initiatives. The remaining 10.2% of imports fall under the 'Other' category, indicating a diversified approach to sourcing additional medical supplies. This product strategy aligns with the WHO's mission to support comprehensive healthcare services by ensuring the availability of necessary diagnostic and medical equipment.

2Sourcing Profile

The WHO's sourcing strategy is characterized by a focus on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, imported from India. This approach suggests a preference for ready-to-use products that meet international quality standards, facilitating efficient distribution and utilization within Pakistan's healthcare system. The reliance on Indian suppliers indicates a strategic choice to leverage established manufacturing capabilities and regulatory compliance within India's pharmaceutical industry.

3Market Positioning

Seller's Guide — How to Become a Supplier to World Health Organization

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with the WHO, provided they can meet the stringent quality and regulatory standards set by DRAP. Gaps in the WHO's current sourcing may exist in areas such as specialized medical devices or emerging pharmaceutical products not currently covered by existing suppliers. Indian exporters can explore these opportunities by ensuring compliance with DRAP's requirements and demonstrating the quality and efficacy of their products.

2Requirements & Qualifications

Indian exporters seeking to supply the WHO and the Pakistani market must obtain a Drug Import License from DRAP and ensure that their products are registered and approved for import. Suppliers must hold valid GMP certifications from recognized authorities, such as WHO or PIC/S, and comply with DRAP's labeling and packaging requirements, including local language labeling and halal certification. Additionally, products must meet DRAP's quality standards, including batch testing and stability requirements.

3How to Approach

Frequently Asked Questions — World Health Organization

What products does World Health Organization import from India?

World Health Organization imports 4 pharmaceutical products across 2 categories. Top imports: Kit ($2.6M), Diagnostic ($691.4K), Reagent ($691.4K), Antitoxin ($450.0K).

Who supplies pharmaceuticals to World Health Organization from India?

World Health Organization sources from 46 verified Indian suppliers. The primary supplier is Sandoz Private Limited (16.4% of imports, $1.9M).

What is World Health Organization's total pharmaceutical import value?

World Health Organization's total pharmaceutical import value from India is $4.4M, based on 200 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does World Health Organization focus on?

World Health Organization imports across 2 categories. The largest: Medical Devices & Diagnostics (89.8%), Other (10.2%).

Get Full World Health Organization Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.